Linker Information
General Information of This Linker
| Linker ID |
LIN0NKJSC
|
|||||
|---|---|---|---|---|---|---|
| Linker Name |
SPDB
|
|||||
| Linker Type |
Unclear
|
|||||
| Antibody-Linker Relation |
Unclear
|
|||||
| Structure |
|
|||||
| Formula |
C8H11NO4S
|
|||||
| Isosmiles |
O=C(N1OC(CCCS)=O)CCC1=O
|
|||||
| PubChem CID | ||||||
| InChI |
InChI=1S/C8H11NO4S/c10-6-3-4-7(11)9(6)13-8(12)2-1-5-14/h14H,1-5H2
|
|||||
| InChIKey |
HPEWNFPWMAYAQB-UHFFFAOYSA-N
|
|||||
| Pharmaceutical Properties |
Molecule Weight
|
217.246
|
Polar area
|
63.68
|
||
|
Complexity
|
228.7639251
|
xlogp Value
|
0.3036
|
|||
|
Heavy Count
|
14
|
Rot Bonds
|
4
|
|||
|
Hbond acc
|
5
|
Hbond Donor
|
1
|
|||
Each Antibody-drug Conjugate Related to This Linker
Full Information of The Activity Data of The ADC(s) Related to This Linker
wO2024181570A1 ADC2 [Investigative]
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | ≈ 0% | Positive CD138 expression (CD138+++/++) | ||
| Method Description |
1x107cells/100 uL, ADC3 at 1 mg/kg, intravenous injection,
|
||||
| In Vivo Model | Capan-1 derived Xenograft Model | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | ≈ 7% | Positive CD138 expression (CD138+++/++) | ||
| Method Description |
1x107cells/100 uL, ADC3 at 1 mg/kg, intravenous injection,
|
||||
| In Vivo Model | Capan-1 derived Xenograft Model | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth lnhibition value (TGl) | ≈ 70% | Positive CD138 expression (CD138+++/++) | ||
| Method Description |
1x107cells/100 uL, ADC3 at 1 mg/kg, intravenous injection,
|
||||
| In Vivo Model | Capan-1 derived Xenograft Model | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
248 ng/mL
|
Positive CD138 expression (CD138+++/++) | ||
| Method Description |
1000 cells/well of Capan-1 in 96 well, 37 °C for 5 days.
|
||||
| In Vitro Model | Pancreatic ductal adenocarcinoma | Capan-1 cells | CVCL_0237 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
274 ng/mL
|
Negative CD138 expression (CD138-) | ||
| Method Description |
1000 cells/well of Jurkat in 96 well, 37 °C for 5 days.
|
||||
| In Vitro Model | T acute lymphoblastic leukemia | Jurkat cells | CVCL_0065 | ||
IN202417078684A+ADC5 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
927 ng/ml
|
|||
| Method Description |
The cytotoxicity of ADC against cell lines was evaluated by cell viability test with CellTiter-Glo 2.0 luminescence method.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
2118 ng/ml
|
|||
| Method Description |
The cytotoxicity of ADC against cell lines was evaluated by cell viability test with CellTiter-Glo 2.0 luminescence method.
|
||||
References